Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacogenetics | 7 | 2014 | 443 | 0.860 |
Why?
|
Polymorphism, Single Nucleotide | 13 | 2017 | 2401 | 0.720 |
Why?
|
Cisplatin | 7 | 2014 | 618 | 0.610 |
Why?
|
Quantitative Trait Loci | 7 | 2017 | 608 | 0.600 |
Why?
|
Proteins | 3 | 2014 | 787 | 0.470 |
Why?
|
Genome-Wide Association Study | 14 | 2017 | 1671 | 0.440 |
Why?
|
Antineoplastic Agents | 3 | 2014 | 2415 | 0.410 |
Why?
|
Population Groups | 1 | 2010 | 41 | 0.370 |
Why?
|
Cell Proliferation | 3 | 2012 | 1652 | 0.360 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2014 | 618 | 0.360 |
Why?
|
RNA-Binding Proteins | 1 | 2012 | 269 | 0.340 |
Why?
|
Cell Line | 9 | 2017 | 2496 | 0.330 |
Why?
|
Lymphocytes | 2 | 2010 | 471 | 0.320 |
Why?
|
Nuclear Proteins | 2 | 2013 | 726 | 0.320 |
Why?
|
Haplotypes | 1 | 2010 | 637 | 0.310 |
Why?
|
B-Lymphocytes | 1 | 2013 | 739 | 0.310 |
Why?
|
HapMap Project | 5 | 2014 | 47 | 0.300 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 1976 | 0.220 |
Why?
|
Apoptosis | 4 | 2014 | 1717 | 0.220 |
Why?
|
Cell Line, Tumor | 6 | 2017 | 2558 | 0.220 |
Why?
|
Proteome | 2 | 2014 | 132 | 0.220 |
Why?
|
Transcription Factors | 3 | 2017 | 1653 | 0.210 |
Why?
|
Cytosine | 2 | 2014 | 128 | 0.210 |
Why?
|
Genes | 2 | 2013 | 305 | 0.190 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2013 | 244 | 0.190 |
Why?
|
Phenotype | 6 | 2014 | 2440 | 0.150 |
Why?
|
Carboplatin | 4 | 2011 | 312 | 0.150 |
Why?
|
Colistin | 1 | 2017 | 7 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2014 | 138 | 0.140 |
Why?
|
Gene Expression | 4 | 2014 | 1310 | 0.130 |
Why?
|
Genetic Variation | 5 | 2014 | 1374 | 0.120 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2013 | 313 | 0.120 |
Why?
|
Genotype | 3 | 2014 | 1849 | 0.120 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2013 | 198 | 0.120 |
Why?
|
Genome, Human | 3 | 2014 | 767 | 0.120 |
Why?
|
DNA Modification Methylases | 1 | 2014 | 28 | 0.120 |
Why?
|
Humans | 19 | 2017 | 89357 | 0.120 |
Why?
|
DNA Repair Enzymes | 1 | 2014 | 55 | 0.110 |
Why?
|
Repressor Proteins | 1 | 2017 | 423 | 0.110 |
Why?
|
Dacarbazine | 1 | 2014 | 102 | 0.110 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
Homeodomain Proteins | 1 | 2017 | 556 | 0.110 |
Why?
|
Caspase 1 | 1 | 2012 | 19 | 0.110 |
Why?
|
Salmonella Infections | 1 | 2012 | 18 | 0.100 |
Why?
|
Cytarabine | 1 | 2013 | 219 | 0.100 |
Why?
|
Salmonella typhimurium | 1 | 2012 | 32 | 0.100 |
Why?
|
Transcriptome | 2 | 2014 | 630 | 0.100 |
Why?
|
Methionine | 1 | 2012 | 65 | 0.100 |
Why?
|
Proteomics | 1 | 2014 | 230 | 0.100 |
Why?
|
Paclitaxel | 1 | 2014 | 479 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 1 | 2014 | 290 | 0.100 |
Why?
|
Nigeria | 1 | 2012 | 156 | 0.100 |
Why?
|
Epistasis, Genetic | 1 | 2012 | 90 | 0.100 |
Why?
|
Genealogy and Heraldry | 1 | 2011 | 13 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 788 | 0.100 |
Why?
|
Organoplatinum Compounds | 1 | 2011 | 97 | 0.100 |
Why?
|
Chromosomes, Human, X | 1 | 2011 | 55 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2012 | 238 | 0.090 |
Why?
|
Platinum | 1 | 2010 | 63 | 0.090 |
Why?
|
Fluorouracil | 1 | 2012 | 561 | 0.090 |
Why?
|
Neuroblastoma | 1 | 2014 | 395 | 0.090 |
Why?
|
Herpesvirus 4, Human | 1 | 2010 | 119 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2013 | 507 | 0.080 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 751 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 316 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 3 | 2014 | 2340 | 0.080 |
Why?
|
Brain Neoplasms | 1 | 2014 | 782 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2013 | 793 | 0.070 |
Why?
|
Signal Transduction | 1 | 2014 | 3385 | 0.060 |
Why?
|
Treatment Outcome | 2 | 2013 | 8241 | 0.060 |
Why?
|
RNA Interference | 2 | 2014 | 376 | 0.050 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 557 | 0.050 |
Why?
|
HEK293 Cells | 2 | 2013 | 640 | 0.050 |
Why?
|
Neoplasms | 1 | 2012 | 3041 | 0.030 |
Why?
|
Drug Resistance | 1 | 2017 | 232 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2014 | 52 | 0.030 |
Why?
|
Cyclohexylamines | 1 | 2014 | 8 | 0.030 |
Why?
|
Plicamycin | 1 | 2013 | 9 | 0.030 |
Why?
|
Quality Control | 1 | 2014 | 117 | 0.030 |
Why?
|
CpG Islands | 1 | 2014 | 157 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 287 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2014 | 302 | 0.030 |
Why?
|
Azacitidine | 1 | 2014 | 147 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 282 | 0.030 |
Why?
|
Thionucleosides | 1 | 2012 | 8 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2013 | 93 | 0.030 |
Why?
|
Caspase 9 | 1 | 2012 | 49 | 0.030 |
Why?
|
Deoxyadenosines | 1 | 2012 | 23 | 0.030 |
Why?
|
Antibodies | 1 | 2014 | 353 | 0.030 |
Why?
|
Southwestern United States | 1 | 2011 | 8 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2013 | 477 | 0.020 |
Why?
|
Capecitabine | 1 | 2012 | 98 | 0.020 |
Why?
|
Glioblastoma | 1 | 2014 | 265 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 262 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2014 | 1076 | 0.020 |
Why?
|
Child | 2 | 2014 | 7174 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2014 | 1214 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 866 | 0.020 |
Why?
|
Genes, X-Linked | 1 | 2011 | 38 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2014 | 956 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2012 | 263 | 0.020 |
Why?
|
Population Surveillance | 1 | 2012 | 216 | 0.020 |
Why?
|
Base Sequence | 1 | 2014 | 2327 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2010 | 64 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 262 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2010 | 155 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2013 | 681 | 0.020 |
Why?
|
DNA Methylation | 1 | 2014 | 657 | 0.020 |
Why?
|
Models, Genetic | 1 | 2014 | 945 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2014 | 1265 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2014 | 2017 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 1242 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 540 | 0.020 |
Why?
|
Cohort Studies | 1 | 2014 | 2872 | 0.020 |
Why?
|
Genetics, Population | 1 | 2010 | 406 | 0.020 |
Why?
|
Risk Assessment | 1 | 2014 | 2303 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 1431 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 3218 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2011 | 3666 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2012 | 6811 | 0.010 |
Why?
|
Young Adult | 1 | 2012 | 6312 | 0.010 |
Why?
|
Male | 2 | 2012 | 42411 | 0.010 |
Why?
|
Mice | 1 | 2012 | 11761 | 0.010 |
Why?
|
Female | 2 | 2012 | 46202 | 0.010 |
Why?
|
Aged | 1 | 2012 | 19165 | 0.010 |
Why?
|
Middle Aged | 1 | 2012 | 25974 | 0.010 |
Why?
|
Adult | 1 | 2012 | 26607 | 0.010 |
Why?
|
Animals | 1 | 2012 | 27371 | 0.010 |
Why?
|